Menu Search
Equities

Xoma Royalty Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
X0M1:DUS

Xoma Royalty Corp

Actions
  • Price (EUR)21.40
  • Today's Change0.40 / 1.90%
  • Shares traded1.00
  • 1 Year change-13.01%
  • Beta0.8614
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

  • Revenue in USD (TTM)47.11m
  • Net income in USD9.87m
  • Incorporated2025
  • Employees13.00
  • Location
    Xoma Royalty Corp2200 Powell Street, Suite 310EMERYVILLE 94608United StatesUSA
  • Phone+1 (510) 204-7200
  • Websitehttps://xoma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		XOMA:NMQ since
announced		Transaction
value
Generation Bio CoAnnounced15 Dec 202515 Dec 2025Announced-1.43%57.89m
HilleVax IncDeal completed04 Aug 202504 Aug 2025Deal completed0.36%97.78m
LAVA Therapeutics NVDeal completed03 Aug 202503 Aug 2025Deal completed0.36%32.61m
Turnstone Biologics CorpDeal completed27 Jun 202527 Jun 2025Deal completed-9.00%5.85m
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.